Tag : BISPECIFIC ADC

Antibody-drug conjugates (ADCs) are a novel class of cancer treatment drugs and are composed of a small molecule cytotoxin linked to a monoclonal antibody. Binding of the circulating ADC to the antigen on the cell surface is the first step required for the internalization of the drug molecule. The drug is then internalized via endocytosis by clathrin-coated endosomes. The endosome is then fused with lysosomes where proteolytic enzymes cleave the linkers between the antibody and the drug is released. Resistance to ADC may be derived from 3 possible processes including antigen expression, ADC processing and the payload itself. During the European Society of Gynaecological Oncology (ESGO) 2024 Congress, Professor Toon Van Gorp from the University Hospital Leuven, Belgium, presented the mechanisms of ADC resistance, as well as several approaches currently being developed to overcome this resistance.